These findings could reflect the heterogeneity observed in the response to monoclonal antibodies targeting IL17A in phase II clinical trials in RA, and raise the question whether targeting other cytokines of the IL-23 axis, including IL-17F and IL-22, may provide additional clinical benefit. Here, IL22 is linked to rheumatoid arthritis.